80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]林 瀟 陳愉生 李鴻茹.查爾森合并癥指數(shù)及簡(jiǎn)化合并癥評(píng)分對(duì)晚期非小細(xì)胞肺癌預(yù)后的影響[J].福建醫(yī)藥雜志,2020,42(05):23-26.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(05):23-26.
點(diǎn)擊復(fù)制

查爾森合并癥指數(shù)及簡(jiǎn)化合并癥評(píng)分對(duì)晚期非小細(xì)胞肺癌預(yù)后的影響()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期數(shù):
2020年05期
頁(yè)碼:
23-26
欄目:
臨床研究
出版日期:
2020-10-20

文章信息/Info

Title:
Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer
文章編號(hào):
1002-2600(2020)05-0023-04
作者:
林 瀟 陳愉生1 李鴻茹2
福建醫(yī)科大學(xué)省立臨床醫(yī)學(xué)院 福建省立醫(yī)院老年科(福州 350001)
Author(s):
LIN Xiao;  CHEN Yusheng;  LI Hongru
Department of Geriatric Medicine, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, China
關(guān)鍵詞:
非小細(xì)胞肺癌;  晚期;  查爾森合并癥指數(shù);  簡(jiǎn)化合并癥評(píng)分;  預(yù)后
Keywords:
non-small cell lung cancer;  advanced;  Charlson comorbidity index;  simplified comorbidity score;  prognosis
分類(lèi)號(hào):
R734.2
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討查爾森合并癥指數(shù)(CCI)和簡(jiǎn)化合并癥評(píng)分(SCS)對(duì)晚期非小細(xì)胞肺癌(NSCLC)患者預(yù)后的影響。方法 回顧性分析我院收治的398例初治晚期NSCLC患者的臨床資料,采用CCI和SCS分別評(píng)估患者的合并癥情況。應(yīng)用Kaplan-Meier法分析合并癥(CCI、SCS)與預(yù)后的關(guān)系。結(jié)果 398例肺癌患者中,高SCS組(SCS≥9分)有51例,低SCS組(SCS<9分)有347例。高CCI組(CCI≥2分)有31例,低CCI組(CCI<2分)有367例。患者確診肺癌后中位總生存期為17個(gè)月,單因素生存分析提示初始治療前血清清蛋白(ALB)、SCS與預(yù)后有關(guān)聯(lián),CCI與預(yù)后無(wú)關(guān)聯(lián)。Cox回歸分析提示初始治療前血清ALB、SCS為影響非小細(xì)胞肺癌患者預(yù)后的獨(dú)立因素。結(jié)論 SCS能快速、簡(jiǎn)便地評(píng)估晚期NSCLC患者的合并癥,是預(yù)后的重要影響因素,值得臨床推廣使用。
Abstract:
Objective To investigate the impact of the Charlson comorbidity index(CCI)and simplified comorbidity score(SCS)on the prognosis of patients with advanced non-small cell lung cancer(NSCLC).Methods The clinical data of 398 patients with newly diagnosed advanced NSCLC admitted to our hospital were retrospectively analyzed.The comorbidities were assessed by CCI and SCS respectively.Kaplan-Meier method was used to analyze the relationship between comorbidities(CCI, SCS)and prognosis of the patients.Results Among the 398 patients with lung cancer, there were 51 cases in the high SCS group(SCS≥9)and 347 cases in the low SCS group(SCS<9).In addition, there were 31 cases in the high CCI group(CCI≥2)and 367 cases in the low CCI group(CCI<2).The median overall survival of the patients after diagnosis of lung cancer was 17 months.Univariate survival analysis suggested that serum albumin(ALB)before initial treatment and SCS were related to prognosis, while CCI was not significantly related to prognosis.Cox regression analysis showed that serum ALB before initial treatment and SCS were independent factors influencing the prognosis of NSCLC patients.Conclusion SCS can evaluate the comorbidities of the patients with advanced NSCLC quickly and easily.It is a key factor influencing the prognosis and is worthy of clinical promotion.

參考文獻(xiàn)/References:

[1] Charlson M E, Pompei P, Ales K L, et al.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J].J Chronic Dis, 1987, 40(5): 373-383.
[2] Colinet B, Jacot W, Bertrandl D, et al.A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the charlsons index[J].British J Cancer, 2005, 93(10): 1098-1105.
[3] Chansky K, Detterbeck F C, Nicholson A G, et al.The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer[J].J Thorac Oncol, 2017, 12(7): 1109-1121.
[4] Singh N, Singh P S, Aggarwal A N, et al.Comorbidity assessment using Charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung cancer[J].Clin Lung Cancer, 2016, 17(3): 205-213.
[5] Haruki T, Yurugi Y, Wakahara M, et al.Simplified comorbidity score for elderly patients undergoing thoracoscopic surgery for lung cancer[J].Surg Today, 2017, 47(6): 718-725.
[6] Alexander M, Evans S M, Stirling R G, et al.The influence of comorbidity and the simplified comorbidity score on overall survival in non-small cell lung cancer-A prospective cohort study[J].J Thorac Oncol, 2016, 11(5): 748-757.
[7] Jacot W, Colinet B, Bertrand D, et al.Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients[J].Ann Oncol, 2008, 19(8): 1458-1464.
[8] Lembicz M, Gabryel P, Brajer-Luftmann B, et al.Comorbidity in patients undergoing surgery for lung cancer.Do we have an adequate tool to assess it?[J].Adv Respir Med, 2017, 85(2): 55-63.
[9] Takemura K, Takenaka Y, Ashida N, et al.Age-adjusted Charlson Comorbidity Index predicts prognosis of laryngopharyngeal cancer treated with radiation therapy[J].Acta Otolaryngol, 2017, 137(12): 1307-1312.
[10] Lee S Y, Kang E J, Lee S Y, et al.Efficacy of second-line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non-small cell lung cancer without epidermal growth factor receptor mutations[J].Oncol Lett, 2018, 15(1): 600-609.
[11] Tanriverdi O, Avci N, Oktay E, et al.Pretreatment serum albumin level is an independent prognostic factor in patients with stage ⅢB non-small cell lung cancer: A study of the Turkish Descriptive Oncological Researches Group[J].Asian Pac J Cancer Prev, 2015, 16(14): 5971-5976.
[12] Lee J H, Wu H G, Kim H J, et al.Influence of comorbidities on the efficacy of radiotherapy with or without chemotherapy in elderly stage Ⅲ non-small cell lung cancer patients[J].Cancer Res Treat,2012, 44(4): 242-250.

相似文獻(xiàn)/References:

[1]林清華　吳聯(lián)平　劉加夫　陳友軒　 齊春能　林玉瓊　黃小紅　鄭　靜.晚期非小細(xì)胞肺癌患者胸水液基細(xì)胞學(xué)蠟塊中新抗體D5F3檢測(cè)的臨床價(jià)值[J].福建醫(yī)藥雜志,2019,41(01):3.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(05):3.
[2]陳新富 劉 寧 劉加夫.CK19在非小細(xì)胞肺癌淋巴結(jié)微轉(zhuǎn)移中的檢測(cè)價(jià)值(附90例分析)[J].福建醫(yī)藥雜志,2020,42(04):6.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(05):6.
[3]李榮賓,黃延延,林賢賓,等.IGF1/RPI3K/Akt通路及其調(diào)控對(duì)非小細(xì)胞肺癌血管生成擬態(tài)形成影響的研究[J].福建醫(yī)藥雜志,2023,45(03):112.
[4]黃陽(yáng),陳靜波,林貴山.動(dòng)態(tài)監(jiān)測(cè)循環(huán)腫瘤細(xì)胞對(duì)寡轉(zhuǎn)移非小細(xì)胞肺癌聯(lián)合治療預(yù)后的價(jià)值[J].福建醫(yī)藥雜志,2023,45(05):8.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(05):8.
[5]鐘穎,鄒立,陳聲池.EGFR T790M突變豐度對(duì)阿美替尼治療晚期非小細(xì)胞肺癌療效的影響[J].福建醫(yī)藥雜志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(05):17.[doi:10.20148/j.fmj.2024.01.005]

備注/Memo

備注/Memo:
1 通信作者,Email: [email protected]; 2 呼吸與危重癥醫(yī)學(xué)科
更新日期/Last Update: 2020-10-20